AACR Meeting 2023 Participation

MW011 - Pathology for Cancer Researchers
Saturday, April 15
8:00AM – 9:30 AM
Location: Room W414 - Convention Center
Lighting Up the Tumor Microenvironment: Multiplexed Spatial Analysis for Research and Clinic
Speaker: Kurt Schalper

MW012 - Utilizing AACR Project GENIE Real-world Clinico-genomic Data
Saturday, April 15
8:00AM – 9:30 AM
Location: Room W311 A-D - Convention Center
Using GENIE Data to Aid in Ancestry-Driven Recalibration of Tumor Mutational Burden And disparate Clinical Outcomes in Response to Immune Checkpoint Inhibitors
Speaker: Amin H. Nassar

DC04 - Making Your Voices Heard: AACR’s Advocacy Efforts with Policy Makers-
Dedicated to the Memory of Chairman John Edward Porter
Saturday, April 15
12:30PM – 1:00PM
Location: Room W314 A - Convention Center
Moderator: Roy S. Herbst

MW004- Clinical Trial Design in a Diverse World, Part 3: Biomarkers in Clinical Trials
Sunday, April 16
2:35PM – 2:55 PM
Location: Valencia D - Convention Center
Standardization, prioritization and optimal use of advanced molecular studies in clinical cancer research
Presenter: Kurt Schalper
CTPL01 - Harnessing the Immune System in the Clinic
Sunday, April 16
3:00PM – 3:10PM
Location: Chapin Theater - Convention Center
Discussant: Roy S. Herbst

MCB09.04 - Signaling Pathways in Cancer Metabolism
Sunday, April 16
1:30PM – 5PM
Location: Section 10
**Differential metabolic adaptations define responses of winner and loser oncogenic mutant cells in skin epidermis in vivo**
Presenters: Anupama Hemalatha and Valentina Greco

TB10.02 - Tumor Heterogeneity
Sunday, April 16
1:30PM – 5PM
Location: Section 5
**Extreme selection constrains ability of EGFR-driven lung adenocarcinoma to diversify in response to erlotinib therapy**
Presenters: J Nicholas Fisk, Stephen Gaffney, Katerina Politi, Scott Gettinger, Fernando De Miguel, Jeffrey Townsend

PS01.01 - Cancer Survivorship
Sunday, April 16
1:30PM – 5PM
Location: Section 27
**Treatment with immune checkpoint inhibitors (ICIs) and the occurrence of colitis among patients with melanoma in the United States**
Presenter: Xiaomei Ma

MCB09.04 - Signaling Pathways in Cancer Metabolism
Sunday, April 16
1:30PM – 5PM
Location: Section 10
**Non-metabolic regulatory functions of nuclear pyruvate kinase M2 induce a MAPK mediated phenotypic switch in invasive cancers**
Presenters: Andre Levchenko, Jesse Rinehart

PR01.01 - Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment
Sunday, April 16
1:30PM – 5PM
Location: Section 28

**Presenters:** Hermine Poghosyan, Sayantani Sarkar, Ilana Richman

**BCS02.01 - Mathematical Modeling of Tumor Growth and Treatment Response**
Sunday, April 16
1:30PM – 5PM
**Location:** Section 31

862 / 20 - Pairwise and higher-order epistatic effects among somatic cancer mutations across oncogenesis of lung adenocarcinoma

**Presenters:** Jorge A. Alfaro-Murillo, Krishna Dasari, Jeffrey P. Townsend

**MS.ET02.01 - Innovative Therapeutic Approaches**
Sunday, April 16
3:07PM - 3:22PM
**Location:** Room W331 - Convention Center

Exploiting MGMT loss using a new class of DNA modifiers which selectively target tumor DNA and overcome therapy resistance mechanisms across multiple tumor types

**Presenters:** Seth Herzon and Ranjit Bindra

**PO.ET02.07 - Drug Delivery Systems**
Sunday, April 16
1:30PM – 5PM
**Location:** Section 15

2715 / 18 - Utilizing a pH sensitive peptide (pHLIP) for tumor targeted delivery of an immunogenic peptide motif

**Presenters:** Annali M. Yurkevicz, Yanfeng Liu, and Peter M. Glazer

**PO.PS01.03 - Aging, Immune Factors, and Metabolomics**
Sunday, April 16
1:30PM – 5PM
**Location:** Section 15

Machine learning-based cluster analysis of immune cell subtypes and breast cancer survival

**Presenter:** Herbert Yu

**PO.CL07.07 - Combination Immunotherapies 2**
Sunday, April 16
1:30PM – 5PM
**Location:** Section 40

A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
**Presenters**: Sarah A. Weiss, Rihao Qu, Ioannis Vathiotis, Myrto Moutafi, Lin Zhang, Ana L. Perdigoto, Wei Wei, Gail Anderson, William Damsky, Michael Hurwitz, Barbara Johnson, Amit Mahajan, Frank Hsu, Kathryn Miller-Jensen, Yuval Kluger, Mario Sznol, Susan M. Kaech, Marcus Bosenberg, Lucia Jilaveanu, and Harriet M. Kluger

**PO.CL09.02 - Molecular Targeted Therapies 1**  
**Monday, April 17**  
1:30PM – 5PM  
**Location**: Section 44  
In vivo efficacy of RAF/MEK clamp avutometinib (VS-6766) in combination with FAK inhibition in low grade serous ovarian cancer  
**Presenters**: Blair McNamara, Cem Demirkiran, Stefania Bellone, Levent Mutlu, Margherita Zipponi, Miguel S. Verzosa, Justin Harold, Tobias M. P. Hartwich, Gary Altwerger, Elena Ratner, Gloria Huang, Mitchell Clark, Vaagn Andikyan, Masoud Azodi, Peter E. Schwartz, Peter Dottino, and Alessandro D. Santin

**PO.CTP01.02 - Phase I Clinical Trials in Progress**  
**Monday, April 17**  
1:30PM – 5PM  
**Location**: Section 46  
First-in-human study of **AZD8853**, an anti-growth and differentiation factor 15 (GDF15) antibody, in patients (pts) with advanced/metastatic solid tumors  
**Presenter**: Pat LoRusso

**PO.CT02.01 - Phase II Clinical Trials 1**  
**Monday, April 17**  
1:30PM – 5PM  
**Location**: Section 47  
**Olaparib +/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial**  
**Presenters**: Kurt Schalper and Patricia LoRusso

**DC03 - FDA Center for Tobacco Products’ Priorities to Address Tobacco Use and Support the Cancer Moonshot**  
**Monday, April 17**  
2:30PM – 4PM  
**Location**: Room W330 - Convention Center  
**Co-Moderator**: Suchitra Krishnan-Sarin

**PO.TB11.04 - Metabolic Influences on the Tumor Microenvironment**  
**Hypoxia induces down-regulation of stimulator of interferon genes (STING) that is synergized with oncometabolites**
PO.ET05.01 - Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy
Concomitant inhibition of Aurora kinase A and WEE1 kinases results in synergistic
tumor control and heightens DNA replication stress in head and neck and lung
carcinomas

PO.ET05.01 - Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy
Mechanistic studies of KL-50, a novel imidazotetrazine for the treatment of MGMT-
/MMR-gliomas and glioblastoma

PO.ET09.03 - Novel Antitumor Agents 3
Prostate cancer RIPTAC™ therapeutics demonstrate activity in preclinical models of
Enzalutamide-resistant prostate cancer

PO.IM01.08 - Immunomodulatory Agents and Interventions 1
Durable eradication of tumors by single injections of a pHLIP-STING agonist
PO.IM01.09 - Immunomodulatory Agents and Interventions 2
TAK-500 is a clinical stage immune-cell directed antibody drug conjugate (iADC) inducing STING activation in CCR2-expressing intratumor myeloid cells and favorable immunomodulation
Monday, April 17
9:00AM – 12:30PM
Location: Section 24
Presenters: Kurt A. Schalper and Angelo Porciuncula

PO.CL07.09 - Immune Response to Therapies
Single cell RNA sequencing defines dynamic immune cell subsets in serial colon and peripheral blood samples in a patient with checkpoint inhibitor-induced colitis
Monday, April 17
9:00AM – 12:30PM
Location: Section 43
Presenters: Jacqueline E. Mann, Liliana Lucca, Matthew Austin, Ross D. Merkin, Lilach Aizenbud, Kevan Herold, Marie Robert, and Harriet M. Kluger

PO.TB11.08 - Tumor-Host Interactions and Disease Progression
Clinical significance of PARP7 (TIPARP) gene copy number alterations in human non-small cell and head & neck carcinomas
Monday, April 17
1:00PM – 5:00PM
Location: Section 6
Presenters: Viviana A. Ahumada, and Kurt Schalper

SS04 - AACR-ASCO Joint Session: Myeloid-targeted Agents for Solid Tumors
Welcome and introductory remarks from the ASCO President
Monday, April 17
4:48PM – 4:50PM
Location: Room W315 - Convention Center
Speaker: Eric Winer

SY31 - Radiation Therapy, DNA Damage, and Immune Response
Exploiting DNA Damage Response Pathways to Stimulate Immunotherapy Response in Glioma
Monday, April 17
12:30PM – 2:00 PM
Location: Room W304 A-D - Convention Center
Speaker: Ranjit S. Bindra

PO.CTP01.01 - Phase I and First-in-Human Clinical Trials in Progress
First-in-human phase 1 studies of PTPN2/1 inhibitors ABBV-CLS-484 and ABBV-CLS-579 in locally advanced or metastatic tumors
Tuesday, April 18
1:30PM – 5:00 PM
**Location:** Section 46
**Presenter:** Patricia LoRusso

**SY25 - The Connection between Autoimmunity and Immunotherapy in Cancer**

**Tuesday, April 18**
10:15 AM – 11:45 AM
**Location:** Valencia BC - Convention Center
**Preclinical Advances in Irae Diagnosis and Management**

**Speaker:** Kevan Herold

**SY34 - Future of Phase I Clinical Trials**

**Tuesday, April 18**
12:30PM – 2:00 PM
**Location:** Room W311 E-H - Convention Center
**Conjugates: Selection, Drug Resistance, And Combinations**

**Speaker:** Patricia M. LoRusso

**CTPL04 - Novel Biomarker-driven Molecularly Targeted Therapy Trials**

**Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations**

**Tuesday, April 18**
11:15AM – 11:30 AM
**Location:** Chapin Theater - Convention Center
**Presenter:** Michael Cecchini

**PO.PS01.02 - GWAS/Post-GWAS**

**Do polygenic risk scores add to clinical data in predicting pancreatic cancer? a scoping review**

**Tuesday, April 18**
1:30PM – 5:00 PM
**Location:** Section 26
**Presenter:** Amy Justice

**PO.CL01.13 - Spatial Proteomics and Transcriptomics 2**

**Tumor immune microenvironment & genomic features of non-small cell lung carcinomas in patients with HIV (PWH)**

**Wednesday, April 19**
9:00AM – 12:30 PM
**Location:** Section 43

**Presenters:** Shruti Desai, Kishu Ranjan, Syim Salahuddin, Ramsey Yusuf, Jianlei Gu, Daiwei Tang, Yong Kong, Barani Kumar Rajendran, Hongyu Zhao, Yuval Kluger, Sarah Goldberg, Brinda Emu, and Kurt Schalper
SY09 - Cancer Ecosystem: Malignant Cells, Microenvironment and More
Wednesday, April 19
10:15AM – 11:45 AM
Location: Valencia A - Convention Center

Autologous Humanized PDX Modeling for Immuno-Oncology Recapitulates the Human Tumor Microenvironment
Speaker: Michael Chiorazzi